Algert Global LLC Has $9.14 Million Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Algert Global LLC increased its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 9.9% in the 3rd quarter, Holdings Channel reports. The firm owned 474,998 shares of the company’s stock after purchasing an additional 42,870 shares during the period. Algert Global LLC’s holdings in Syndax Pharmaceuticals were worth $9,144,000 as of its most recent filing with the SEC.

A number of other large investors have also recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Syndax Pharmaceuticals by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock worth $58,000 after purchasing an additional 541 shares during the last quarter. Sei Investments Co. lifted its holdings in shares of Syndax Pharmaceuticals by 2.5% during the first quarter. Sei Investments Co. now owns 40,463 shares of the company’s stock worth $963,000 after buying an additional 991 shares during the last quarter. California State Teachers Retirement System boosted its position in shares of Syndax Pharmaceuticals by 1.5% in the first quarter. California State Teachers Retirement System now owns 76,557 shares of the company’s stock valued at $1,822,000 after acquiring an additional 1,150 shares during the period. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Syndax Pharmaceuticals in the second quarter valued at approximately $27,000. Finally, Ameritas Investment Partners Inc. grew its stake in shares of Syndax Pharmaceuticals by 20.0% in the first quarter. Ameritas Investment Partners Inc. now owns 7,858 shares of the company’s stock worth $187,000 after acquiring an additional 1,312 shares during the last quarter.

Syndax Pharmaceuticals Stock Performance

Syndax Pharmaceuticals stock opened at $16.09 on Friday. The business has a 50 day simple moving average of $18.66 and a 200 day simple moving average of $20.05. Syndax Pharmaceuticals, Inc. has a one year low of $15.00 and a one year high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.13) by $0.15. The company had revenue of $12.50 million for the quarter, compared to analyst estimates of $9.16 million. During the same quarter in the prior year, the company earned ($0.73) earnings per share. As a group, sell-side analysts anticipate that Syndax Pharmaceuticals, Inc. will post -3.69 EPS for the current fiscal year.

Analysts Set New Price Targets

SNDX has been the subject of a number of research reports. The Goldman Sachs Group increased their price target on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. upped their price objective on shares of Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an “overweight” rating in a research report on Thursday. Stifel Nicolaus lifted their target price on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. StockNews.com cut Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday. Finally, HC Wainwright raised their price objective on Syndax Pharmaceuticals from $49.00 to $51.00 and gave the stock a “buy” rating in a research report on Monday, November 18th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, Syndax Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $37.64.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).